Compare Ginkgo Bioworks Holdings Inc (DNA) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Fidelity National Information Servcs Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Fidelity National Information Servcs Inc trades at $34.08 (market cap $17.71B). The key difference: Fidelity National Information Servcs Inc is far larger — about 23.2× Ginkgo Bioworks Holdings Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Fidelity National Information Servcs Inc for 88 Days on average.
| DNA | FIS | |
|---|---|---|
Market Cap | $763.64M | $17.71B |
Volume | 3,204,177 | 9,047,825 |
Sector | Health | Technology |
52-Week High | $15.83 | $68.57 |
52-Week Low | $5.48 | $32.44 |
Typical Hold Time | 7 Days | 88 Days |
Enterprise Value | $865.59M | $38.22B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
FIS trades at $34.04, up 0.65% on the day, with a bearish technical signal from moving averages and oscillators. The company's valuation metrics appear attractive with a P/E of 5.27 and P/S of 1.46, while recent earnings have shown beats in Q1 and Q2 2026. Revenue is projected to grow to $12.2B in 2026, with net income margin improving to 27.64%. Recent news highlights contract wins and platform modernizations, supporting growth momentum.
The outlook for FIS is cautiously optimistic, with strong analyst support (56.76% buy ratings) and a consensus price target of $47.15 implying significant upside. However, risks include a high debt-to-asset ratio of 39.06% in 2025 and volatile cash flow trends. Investors should weigh the low valuation against execution risks and macroeconomic pressures in the financial technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
